Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
Elnaz Khani, Taher Entezari‐Maleki
Topics & Concepts
FluvoxamineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakSigma-1 receptorReceptorVirologyPharmacologyPsychologyMedicineAgonistInternal medicineFluoxetineSerotoninDiseaseInfectious disease (medical specialty)OutbreakPharmacological Receptor Mechanisms and EffectsEpilepsy research and treatmentPhenothiazines and Benzothiazines Synthesis and Activities